New Pathway for Stalling BRCA Tumor Growth Revealed
Inhibiting the action of a particular enzyme dramatically slows the growth of tumor cells tied to BRCA1 and BRCA2 genetic mutations which, in turn, are closely tied to breast and ovarian cancers. If further experiments prove successful, these findings could lead to a new class of targeted therapies against cancers with BRCA1 and BRCA2 mutations. [Press release from NYU Langone Medical Center discussing online publication in Nature] Press Release|Abstract
The Breast Cancer Susceptibility FGFR2 Provides an Alternate Mode of HER2 Activation
Scientists show that mouse mammary tumor virus-neu mice develop breast carcinomas with fibroblast growth factor receptor 2 (FGFR2) immunoreactivity that parallels HER2 expression. Functionally, FGFR2 facilitates HER2-mediated cell proliferation, acinar growth in three-dimensional morphogenesis assays and promotes tumor progression in mouse xenografts. [Oncogene] Abstract
Beclin 1 Regulates Growth Factor Receptor Signaling in Breast Cancer
Investigators describe an alternative mechanism of action for beclin 1 in breast cancer involving its control of growth factor receptor signaling. Suppression of BECN1 sustains growth factor-stimulated AKT and ERK activation resulting in increased breast carcinoma cell invasion. [Oncogene] Abstract
MicroRNAs in Breast Cancer: Regulatory Roles Governing the Hallmarks of Cancer
The authors provide a comprehensive overview of microRNAs (miRNAS) with established functional relevance in breast cancer, their established target genes and resulting cellular phenotype. They also summarize the role of miRNAs in the hallmarks of breast cancer, as well as the possibility of using miRNAs as potential biomarkers for detection of breast cancer. [Biol Rev] Abstract
Visit our reviews page to see a complete list of reviews in the mammary cell research field.
INDUSTRY NEWS
Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (Palbociclib)
Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of IBRANCE® (Palbociclib), in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. [Pfizer Inc.] Press Release
New Clinical Trial for Breast and Ovarian Cancer Vaccine
University of Colorado Hospital is one of just two academic medical centers in the nation that has enrolled breast and ovarian cancer patients to a new clinical trial of a promising cancer vaccine. The trial focuses on the safety and early test for effectiveness of ONT-10, an immunotherapy made by Oncothyreon. [University of Colorado Hospital] Press Release
Cord Blood Registry Announces Formation of Scientific & Medical Advisory Board
Cord Blood Registry® (CBR®) announced the establishment of a Scientific and Medical Advisory Board (SMAB). Composed of internationally renowned stem cell experts, the SMAB will provide input and guidance to help advance CBR’s mission to expand the scope of newborn stem cell therapies that may be available to patients and their families. [Cord Blood Registry®] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!
![[Free On-Demand Webinar] Detect Cancer Stem Cells with ALDEFLUOR™ - Watch Now.](http://img.en25.com/eloquaimages/clients/StemcellTechnologiesInc/{87cda00f-ac85-49b9-866e-b67e0756b6b7}_ON393_VerA-Aldefluor_CSC_webinar_A_645x110.jpg)
